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Abstract
Background: Current guidelines set out when to start anticancer treatments, but not when to stop as the end of
life approaches. Conventional cytotoxic agents are administered intravenously and have major life-threatening toxicities.
Newer drugs include molecular targeted agents (MTAs), in particular, small molecule kinase-inhibitors (KIs), which are
administered orally. These have fewer life-threatening toxicities, and are increasingly used to palliate advanced cancer,
generally offering additional months of survival benefit. MTAs are substantially more expensive, between £2-8 K per
month, and perceived as easier to start than stop.
Methods: A systematic review of decision-making concerning the withdrawal of anticancer drugs towards the end of life
within clinical practice, with a particular focus on MTAs. Nine electronic databases searched. PRISMA guidelines followed.
Results: Forty-two studies included. How are decisions made? Decision-making was shared and ongoing, including
stopping, starting and trying different treatments. Oncologists often experienced ‘professional role dissonance’
between their self-perception as ‘treaters’, and talking about end of life care. Why are decisions made? Clinical
factors: disease progression, worsening functional status, treatment side-effects. Non-clinical factors: physicians’
personal experience, values, emotions. Some patients continued treatment to maintain ‘hope’, often reflecting
limited understanding of palliative goals. When are decisions made? Limited evidence reveals patients’ decisions
based upon quality of life benefits. Clinicians found timing withdrawal particularly challenging. Who makes the
decisions? Decisions were based within physician-patient interaction.
Conclusions: Oncologists report that decisions around stopping chemotherapy treatment are challenging, with
limited evidence-based guidance outside of clinical trial protocols. The increasing availability of oral MTAs is
transforming the management of incurable cancer; blurring boundaries between active treatment and palliative
care. No studies specifically addressing decision-making around stopping MTAs in clinical practice were identified.
There is a need to develop an evidence base to support physicians and patients with decision-making around
the withdrawal of these high cost treatments.
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Background
Decision-making around starting and stopping treatment
in advanced cancer is challenging for all concerned; pa-
tients, families and healthcare professionals alike. Appro-
priately timed cessation of treatment is an internationally
recognised cancer treatment quality indicator [1–4], yet
recent years have seen a trend towards continuing treat-
ment until close to the end of life [5–7], at times within
weeks of death [5, 7, 8]. In the UK, following a national
audit of morbidity and mortality associated with chemo-
therapy, death within 30 days of receiving chemotherapy
is now an accepted standard with an expectation that con-
tinuing chemotherapy in the last month of life is futile [9].
Recent research has demonstrated palliative cytotoxic
chemotherapy at the end of life to be associated with a
host of adverse outcomes including cardiopulmonary re-
suscitation, death in intensive care unit, place of death less
likely to be at home or in preferred place and late hospice
referral, as well as no survival benefit [10, 11].
Increased prescribing of cancer treatments over longer
periods of time has been linked to availability of a pleth-
ora of new anti-cancer drugs, particularly the molecular
targeted anticancer agents (MTAs) such as small molecule
kinase inhibitors (KIs) [12, 13]. MTAs have been shown to
improve outcomes in a variety of advanced malignancies,
including chronic myeloid leukaemia, acute myeloid
leukaemia, non-Hodgkin lymphomas, gastrointestinal
stromal tumours (GIST), melanoma, renal and breast
cancers [12, 14–16]. Notably, kinase-inhibitors (KIs)
have improved survival in traditionally chemoresistant
cancers, including advanced non-small cell lung can-
cer (NSCLC) [17–19], melanoma [20, 21] and renal
cell cancer [22, 23].
Over recent years, MTAs have therefore transformed
cancer management and their number is set to continue
to increase over time [12, 14]. In addition to survival
gains, oral MTAs allow for flexibility in care-planning,
since patients administer their own treatment at home,
avoiding hospital visits [24]. Although not without side-
effects, MTA-induced toxicities are rarely life threatening
with significantly lower rates of myelosuppression com-
pared with conventional cytotoxic chemotherapy [14].
Eligibility to access MTAs is well defined by drug li-
censing indications, but stopping treatment, by contrast,
is very different. RECIST (Response Evaluation Criteria
In Solid Tumours) criteria are widely used within clinical
trials for stopping treatment, based on proportional in-
crease in tumour measurements during therapy [25]. Out-
side of trials, decision-making is far less tightly controlled
and subjective endpoints influence decision making. Fur-
thermore, recent evidence suggests that MTAs may im-
prove survival despite RECIST evidence of measurable
disease progression [26, 27]. Continued treatment with
MTAs despite tumour growth is also being influenced by
reports of rebound progression or “disease flare” on stop-
ping therapy [20, 21, 28, 29]. There is also growing evi-
dence of survival benefit from MTA re-challenge after a
period off treatment in Non-Small Cell Lung Cancer
(NSCLC) [28], and Gastrointestinal Stromal Tumour
(GIST) [30] and renal cell cancer [31].
In most cases, the survival benefits of MTAs when treat-
ing patients with advanced solid tumours is measured in
months rather than years [12, 14–16]. Costing between
£2000 and £8000 per month, they impose considerable
pressure on individuals and financially constrained health-
care systems. [32] There is therefore a strong health eco-
nomic argument to ensure that guidance is available to
support discontinuation of MTAs for reasons of futil-
ity. A systematic review of the literature was therefore
undertaken, to identify current knowledge concerning
decision-making in clinical practice to withdraw antican-
cer treatment in patients with advanced solid tumours.
Aims
To examine decision-making concerning the withdrawal
of anticancer treatments in patients with advanced solid
tumours outside of clinical trials, with particular regard
to MTAs:
(1)How are these decisions made?
(2)Why are these decisions made?
(3)Who makes these decisions?
(4)When are these decisions made?
Methods
We undertook a systematic search of the international lit-
erature, utilising a thematic approach to analysis [33] and
a narrative synthesis for presenting the findings [34].
Search strategy and selection criteria
Nine electronic databases (AMED (Allied and Complemen-
tary Medicine Database), ASSIA (Applied Social Sciences
Index and Abstracts), BNI (British Nursing Index),
CINAHL (Cumulative Index of Nursing and Allied
Health Literature), Embase, MEDLINE, PsychINFO, SSCI
(Social Sciences Citation Index), Cochrane Library) were
searched for papers published between January 2003 and
August 2013, using search strategies developed in con-
junction with a professional librarian (IK) (Fig. 1). The
grey literature was searched using the NHS evidence data-
base, policy institute websites and charity and healthcare
websites. Hand-searches of Lancet Oncology, British Jour-
nal of Cancer, Annals of Oncology and Journal of Clinical
Oncology were undertaken, with reference and citation
searches of all included papers. PRISMA guidelines were
followed [35].
Inclusion criteria: studies of decision-making concerning
cessation or continuation of oral or parenteral treatments
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for advanced malignant disease; qualitative or quantitative
research methods; treatments being used in clinical prac-
tice; abstract or full paper available in English language.
Studies investigating MTAs were particularly sought.
Exclusion criteria: children under age 18, discussion or
opinion pieces containing no new empirical data, steroids,
bisphosphonates, treatment with radiation therapy only
and clinical trial data.
Data extraction, quality evaluation and analysis
Abstracts were screened by three authors (GC: social
scientist, SJ: medical oncologist, SB: GP and palliative
specialist) and full papers screened by GC and SJ who
also independently assessed study quality using Gough’s
Weight of Evidence framework [36]. Studies rated ‘high’
were given greater weight. A qualitative sensitivity ana-
lysis was performed [37]. We excluded studies rated as
‘low quality’ and assessed whether the findings were al-
tered by this exclusion. Firstly, we examined whether
any of the analytics themes were lost; and secondly we
examined whether any of the ‘depth’ of the findings was
lost. Data was entered into a review-specific data extrac-
tion form and then into NVivo9 for a narrative synthesis
using a “thematic approach” [33].
Ethics
This study did not require approval by an ethics committee
as it is a systematic literature review of previously pub-
lished work. PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) guidelines for
a systematic review were followed [35].
Results
Searches yielded 8368 citations, 371 abstracts and 81 full
papers were assessed. A total of 42 papers met the in-
clusion criteria and were included in the final analysis.
Fig. 2 summarises this process.
Numbers of included papers are indicated in square
brackets [ ]. Thirty-two papers (76 %) investigated deci-
sions to stop treatment for a range of solid and haemato-
logical cancers. Ten (24 %) examined specific malignancies:
lung [4], pancreas [2] and 1 each for ovarian, breast, lung
and colorectal, colorectal and breast cancers. Most
examined chemotherapy in general rather than spe-
cific drug regimens. Two papers discussed the use of
MTAs in the final months of life [38, 39], and a fur-
ther three briefly commented on MTAs [40–42]:
none described decision making processes concerning
stopping MTAs close to the end of life. Papers came
from 14 different countries, some studies comprised
evidence from multiple countries: USA [15], Netherlands
[5], UK [4], Japan [3], 2 each from New Zealand, Canada,
Italy and Sweden and 1 each from Germany, Australia,
Taiwan, Belgium, Korea, UK with USA, and Australia
with Israel. Twenty-four of these studies contained
primarily qualitative data, and 18 contained primarily
quantitative data. Additional file 1 [see Additional
file 2] summarises the main characteristics of in-
cluded studies. The sensitivity analysis revealed that re-
moving studies rated as low quality did not alter the
overall findings; no themes or topics were lost, and
only a small amount of the ‘depth’ or ‘thickness’ of the
findings was lost.
Fig. 1 Cross-tabulation illustrating example search terms and strategy for an electronic database
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(1) How are decisions made?
The process of treatment withdrawal was described as a
shared progression of many different conversations rather
than a one-off decision [11, 38, 40, 42–50]. It involved
a trajectory of repeated reassessments and trying differ-
ent treatment options [13, 38, 40, 42–50], including
treatment breaks before starting subsequent new regimens
[4, 38, 40, 42, 50]. MTAs contribute to this process by pro-
viding more options before cessation of all treatment
[2, 38, 39]. Decisions about withdrawing treatment
were described as an integral part of patient care [45],
strongly influenced by patients’ views and wishes [51]. Collu-
sion in continuing inappropriate treatment may occur un-
less both oncologist and patient are ready to discuss
stopping treatment and both acknowledge that the end of
life is near [38].
Oncologists commonly report finding discussions about
stopping treatment difficult [6, 38, 42, 44, 46, 50, 52] and
emotionally challenging [3, 38, 49, 52].
“What I like least [about my job] is giving people bad
news. It’s just terrible. It’s just horrible. It’s so sad…It’s
just horribly sad.” (Oncologist) [38]
Clinicians reported that discussions around stopping
treatment are commonplace and challenging, with a
limited evidence base outside of clinical trial protocols
available for guidance [38]. The ‘grey area’ in which patients
want another line of chemotherapy and their condition
could permit it, but on the balance benefits and burdens it
would be inadvisable, is particularly challenging [52]. The
process of withdrawing treatment involves switching role
from that of an “advocate” for curative or disease modifying
treatments to a supportive “counselling” role for palliative,
end of life care [49]. This role switch may create “role
dissonance” for oncologists who often perceive themselves
as “treaters” who “do something” [38]. Clinicians may be-
come “stuck” on an “institutional script for treatment” [46]
which prevents them from discussing alternative support-
ive interventions, “watchful waiting” [53], or discussions
concerning death and dying [46, 54].
Stopping treatment may be raised by clinicians as a new
direction of treatment in which the patient’s emotions are
directly addressed [42], or by presenting it as a “biological
fact” that leaves little room for discussion:
“And so we started you off with the standard
treatment. . . .We didn’t quite see what we wanted
with that, we moved on to something else. One thing I
just want to make sure you realize is that we don’t
save our best weapons for the end. We use them up
front. So the chances of you responding to other agents,
are even less than the chances were with the two other
regimens you’ve already gotten”. (Oncologist talking to
patient) [42]
Some oncologists describe a “contemplation stage”
during which evidence is gathered concerning disease
progression and treatment options and consideration
given on how to present this to the patient [38, 49, 52].
Fig. 2 Flow diagram illustrating systematic search process
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Few studies addressed the involvement of patients
and their supporters in treatment cessation decisions.
Oncologists expressed the view that patients need to be
beginning to accept their terminal status before they can
be ready to consider stopping treatment [3, 44, 47, 51], for
some this acceptance may not happen until very close to
death [44]. Patients with greater experience of treatment
may be more confident about negotiating treatment op-
tions and being involved in decisions [48]. Those with
strong belief in the effectiveness of the treatment may have
it continued longer [55]. Some patients withdraw from the
decision-making process as their disease progresses and a
surrogate decision-maker takes over [51, 53]. A perception
that doctors do not wish to involve family members in dis-
cussions may cause considerable distress [56].
(2) Why are decisions made?
Decisions to stop treatment are complex and multifaceted,
with four major factors identified from the literature.
(a) Disease and clinical factors: Key factors in decisions
to stop treatment included worsening patient condition or
functional status [10, 38, 43, 44, 49, 52, 55, 57–60] disease
progression or advanced stage disease [9, 38, 40, 43, 44,
47, 49, 52, 57, 60] and treatment side effects [7, 38, 49, 52,
55, 59–61]. Patients who received their diagnosis when
only in advanced disease, and patients who had not re-
ceived treatment earlier in the course of illness for
other reasons, often had their therapy extended much
longer than patients who had received earlier treat-
ments [5, 38, 62–65].
The type of cancer influenced treatment decisions [7, 38,
43, 49, 60, 62, 64, 66]. For example, patients with haemato-
logical malignancies [4, 38, 43, 62, 63], and advanced lung
cancers [2, 38, 64], were more likely to have their treat-
ment continued. Chemo-responsiveness of tumours was
reported to be a key factor in decisions to continue treat-
ment [2, 43, 66], although two population-based studies
found no such connection [41, 67]. Six population studies
found treatment was more likely to be withdrawn or with-
held in older people [57, 58, 62, 63, 67, 68], although one
study found age was not a predictor of discontinuing pal-
liative treatment [60].
(b) Clinician-dependent factors: A range of non-
clinical factors influenced decision-making in the face of
cancer progression. Clinicians’ personal approaches,
heavily shaped by their personal perspectives and ethics
[6, 38, 43, 49, 52, 69, 70] were significant predictors of
whether chemotherapy was continued as disease pro-
gressed [2, 57, 66] Doctors’ views of patients’ personal-
ities and circumstances also influenced the decision [4,
38, 43, 49, 70].
“I think instinctively you feel that this is a young
patient with a young family you need to make even
more effort to try and help them live for a bit longer”.
(Oncologist) [49]
Some doctors reported they would continue treatment
within two weeks of death for even a small chance of pos-
sible extension of life [39]. Treatment was also more likely
to be continued by younger and less experienced doctors
[2, 38, 43], and in the face of uncertainty of clinical benefit
[38, 39].
“We are poor predictors of prognosis even in these near
death time frame and we therefore err on the side of
more treatment.” (Oncologist) [39]
Treatment was often continued to avoid “taking away
hope” [4, 38, 49, 52, 71] and when strong relationships
have developed with patients [3, 43, 44, 72].
(c) Patient-dependent factors: Hope for the future was
an important driver for patients’ decision-making [3,
44, 47, 48], although this hope at times reflected poor
understanding of the palliative rather than curative
aims of treatment [4, 48, 72–75]. When making deci-
sions, patients strive to balance hope and improvements in
quality of life, with side-effects and the burdens of treat-
ment [5, 51, 55, 61, 63, 68]. Older patients are more likely
to discontinue treatment when approaching the end of life
[8, 57, 58, 62–64, 66, 67], although one study found no such
association [60].
(d) Environmental factors: Hospital setting was a key
influence on whether or not treatment was continued
[6, 38, 39, 57, 60, 62, 76, 77]. Treatment was more
likely to be continued in teaching hospitals [62], and
those receiving private treatment in physicians’ offices,
rather than in general hospital outpatient clinics [77].
Access to and information about palliative care services
was associated with stopping treatment [3, 39, 57, 60],
as was having a supportive care plan in place [54], al-
though hospice referral was not always associated with
treatment discontinuation [54].
Treatment costs also influence these decisions, par-
ticularly in health systems where patients have to meet
drug costs personally [3, 38, 39, 77]. The availability of
new MTAs, although expensive, influence decisions to
continue treatment as they provide additional options
for continuation of treatment [3, 38, 39, 43].
(3) When are decisions made?
The literature concerning the timing of decisions to with-
draw treatment was very limited. Clinicians expressed
great difficulty over judging the appropriate time to
stop [5, 38, 43, 44, 48, 49], particularly when a pa-
tient’s condition could justify, but the prognosis was
unclear and the benefit of treatment was uncertain
[52]. Patients also expressed uncertainty about the
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timing of treatment withdrawal. In one study, all par-
ticipants unanimously emphasised the difficulty of
anticipating the right time to make the decision to
stop all treatment [48].
(4) Who makes the decision?
The majority of studies reporting upon ‘who makes the deci-
sion’, found decision-making was an on-going process based
in the interaction between the physician and patient, and
sometimes close relatives [8, 38, 40, 43, 45, 48, 49, 52, 73].
However there was mixed evidence upon who in reality
was involved in decision-making and who made the
final decision. One study reported fewer patients to
have been involved in the decision-making process than
wanted to be, and that only half of competent patients
were involved [78]. In contrast, another study reported
family members to believe that the patients’ preferences
had been followed in 78 % of cases [79]. Nurses often
have an important supportive role [4, 43, 52, 57, 61], as
may the wider multidisciplinary team [49].
A smaller number of studies found decisions were driven
by one particular party: four studies found decision-making
was patient driven, two of these studies were based in the
USA, one was based in The Netherlands and the other in
Israel and Australia [39, 44, 51, 52]; in contrast three studies
found physicians had the strongest influence, one on these
studies was based in the USA, one in New Zealand and one
in the Netherlands [43, 52, 71]. The number of studies and
the limited high quality evidence on this topic means that
no effect by country or continent could be found.
Doctors exerted influence by choosing which options
to present to patients [43], and the way in which those
options were presented [52]. Some patients preferred
not to be involved in the decision-making at all [48],
while for others feeling in control was important, even if
it was only control of day-to-day decisions [44, 48, 80].
“I want to be able to have control or say about my
illness, whether I think I should take chemo or not.
The doctors tried to talk me out of it [her decision to
stop treatment], and it’s just like, it’s MY body. I feel
it’s not going to do anything for me. It’s making me
sicker so why do it? I felt that it was important for me
to have control over that.” (Patient declining
chemotherapy in advanced disease) [80].
Discussion
Deciding that “enough is enough”, that cancer treatment
should be stopped in the face of approaching end of life,
is one of the most challenging decisions that patients,
their families and oncologists have to make. Based on
limited published evidence primarily derived from the
USA, these decisions appeared to be made over a period
of time, in the context of an ongoing and trusting
relationship between oncologist and patient, and were
largely clinician-guided. Clinical factors such as disease re-
sponse and progression dominated treatment decision-
making, with physicians having to weigh up the potential
“costs” of the treatment to the patient such as side-effects
and toxicities, with potential “benefits” such extended life-
span or giving the patient hope for the future.
The decision to continue or stop cancer chemotherapy
has costs associated, both to the patient and the wider
health economy. While MTAs have fewer life threaten-
ing toxicities than conventional cytotoxic chemotherapy,
common toxicities including rash, diarrhoea and intersti-
tial pneumonia generate hospital admissions [81, 82].
Multi-targeted Vascular Endothelial Growth Factor
Receptor Tyrosine-Kinase Inhibitors (VEGFR TKIs) are
associated with haemorrhage, hypertension, adrenal dys-
function, hypothyroidism and acute coronary syndrome
[83]. Some BRAF (B-Raf proto-oncogene, serine/threo-
nine kinase) targeted inhibitors are associated with
chronic photosensitivity and risk of skin squamous cell
cancers [84]. Many MTAs cause fatigue [14], which may
significantly impair quality of life.
However, subtle factors such as clinicians’ attitudes
and personalities, doctor-patient relationships and rela-
tives’ and patients’ views strongly influenced decisions. A
concern to foster ‘hope for the future’ was a significant
factor for all parties, but at times, this hope was unreal-
istic, reflected poor understanding of palliative treat-
ments, or arose from physician collusion. These findings
show that the nature of the patient-physician relation-
ship is a key part of decision-making concerning the
withdrawal of anticancer drugs towards the end of life,
and add growing support to the body of knowledge on
the importance on ‘trust’ and ‘rapport’ in shared health-
care decision-making [85, 86].
To our knowledge, this is the first systematic review of
decision-making concerning withdrawing anticancer treat-
ments in advanced disease within clinical practice. We used
a rigorous and inclusive search strategy to comprehensively
search the international literature, including nine electronic
databases and grey literature. A broad range of study popu-
lations and methodologies were included, incorporating evi-
dence from both qualitative and quantitative studies. Several
factors indicate the robustness of the findings: the themes
identified were repeated across a large proportion of the
studies, despite the heterogeneous contexts and populations;
the themes did not vary substantially across different coun-
tries; and the sensitivity analysis revealed that removing
studies rated as ‘low’ did not alter the findings of the review.
This review does have several limitations. There is lim-
ited high quality evidence: using Gough’s weight of evi-
dence framework [36] only nine studies were rated as
high quality, 15 as medium and 18 as low quality. Many
of the low rated studies had a small sample size or
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limited evidence relevant to the review questions. Higher
quality studies were given greater weighting in the
thematic analysis, although sensitivity analysis revealed
that removing studies rated as ‘low’ did not alter the
findings of the review. The heterogeneous nature of in-
cluded studies made comparisons difficult; we selected a
thematic analysis and narrative synthesis methodology
to account for this. Only studies published in English
language were included: although the included studies
had a wide international range, 38 % (16/42) of included
papers were from Europe, 36 % (15/42) from the United
States and 12 % (5/42) from Asia. Clinical practice may
be particularly different in the US where patients may
exert pressure to continue treatment and clinicians have
personal financial incentives to prolong treatment.
Conclusions
The advent of molecular targeted agents (MTAs) has
brought new benefits as well as challenges to modern
cancer therapy, potentially blurring the distinction be-
tween active and palliative interventions. Traditionally,
disease progression is an indication to stop treatment,
but outside of trials, stopping treatment is far more chal-
lenging. Furthermore, there is evidence to show that pa-
tients receiving oral MTAs continue treatment until
closer to death than those receiving intravenous antican-
cer therapies [38, 39, 41, 69]. While it is generally con-
sidered that continuing treatment in the last 30 days of
life must be futile from a biomedical perspective, there
may be benefit in continuing MTA treatment beyond
disease progression [26], particularly given the potential
for “tumour flare” on stopping these therapies [26]. It
has been suggested that for modern targeted therapies,
the definition of disease progression may itself need re-
defining [16, 27]. It remains unclear how best to inte-
grate MTAs into modern treatment algorithms [16, 27].
Wider subjective factors clearly influence treatment
decision-making and the relative balance of harms and
benefits associated with patients, carers and doctors
choosing to continue anticancer drugs beyond disease
progression has not yet been determined. While MTAs
offer real hope for patients with advanced cancers, their
considerable financial costs are raising major health eco-
nomic and ethical concerns in resource-constrained health
services across the world. With rising cancer incidence
and increasing numbers of patients on MTA treatment
across the world, it is important for clinical practice, as
well as society as a whole, to have realistic expectations of
these new agents. We found no studies which specifically
addressed decisions concerning when to stop treatment
with MTAs. While the recent development of these agents
may in part be responsible for the lack of research, there is
clearly a pressing need to develop an evidence-base to
allow physicians to weigh up the potential ‘costs’ and
‘benefits' of these treatments and inform optimal decision-
making associated with stopping MTAs.
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